Is pain linked to mortality risk in patients with psoriatic arthritis?April 5, 2021Psoriatic Arthritis
FDA warning letters target OTC cannabidiol product claims for pain reliefMarch 25, 2021Psoriatic Arthritis
Checkpoint inhibitor–induced rheumatic complications often arise lateMarch 15, 2021Psoriatic Arthritis
To improve psoriatic arthritis outcomes, address common comorbiditiesMarch 12, 2021Psoriatic Arthritis
Recent psoriasis pathophysiology insights carry treatment implicationsMarch 4, 2021Psoriatic Arthritis
Methotrexate-associated hepatotoxicity risk differs between psoriasis, PsA, and RA patientsFebruary 25, 2021Psoriatic Arthritis
Pandemic puts patients with psoriatic disease off seeking medical helpFebruary 23, 2021Psoriatic Arthritis
Anybody for a nanobody? Novel psoriasis therapy impresses in phase 2bFebruary 10, 2021Psoriatic Arthritis
Rheumatologic disease activity an important influencer of COVID-19 death riskFebruary 5, 2021Psoriatic Arthritis
FDA alert confirms heart and cancer risks with tofacitinib (Xeljanz)February 5, 2021Psoriatic Arthritis
In head-to-head trial, two biologics differ markedly for control of psoriasisFebruary 4, 2021Psoriatic Arthritis
